Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins
June 14th, 2018
11.2K views
Here, we present a protocol to genetically modify primary or expanded human natural killer (NK) cells using Cas9 Ribonucleoproteins (Cas9/RNPs). By using this protocol, we generated human NK cells deficient for transforming growth factor–b receptor 2 (TGFBR2) and hypoxanthine phosphoribosyltransferase 1 (HPRT1).
Overview
This article presents a protocol for genetically modifying human natural killer (NK) cells using Cas9 Ribonucleoproteins (Cas9/RNPs). The method allows for the generation of NK cells deficient in TGFBR2 and HPRT1, facilitating research into NK cell biology and immunotherapy.
Key Study Components
Area of Science
- Neuroscience
- Immunology
- Gene Editing
Background
- Natural killer (NK) cells play a crucial role in the immune response.
- Understanding gene functions in NK cells can enhance immunotherapy approaches.
- Current methods for gene editing in NK cells have limitations.
- This protocol aims to improve the efficiency of gene knockout in NK cells.
Purpose of Study
- To establish a reliable method for modifying NK cells.
- To investigate the roles of specific genes in NK cell function.
- To explore implications for immunotherapy targeting solid tumors.
Methods Used
- Isolation and culture of primary NK cells in RPMI medium.
- Transduction of NK cells using IL2 and feeder cells.
- Electroporation for introducing Cas9/RNPs into NK cells.
- Assessment of gene knockout efficiency and functionality.
Main Results
- Successful generation of NK cells deficient in TGFBR2 and HPRT1.
- High success rate of gene knockout compared to traditional methods.
- Potential applications in enhancing NK cell therapy for tumors.
- Insights into the mechanisms of immune escape in tumors.
Conclusions
- The protocol provides a robust approach for NK cell modification.
- Findings contribute to understanding NK cell biology and therapy.
- Future studies can leverage this technique for clinical applications.
Frequently Asked Questions
What are Cas9 Ribonucleoproteins?
Cas9 Ribonucleoproteins are complexes used in gene editing that consist of the Cas9 enzyme and a guide RNA.
How does this method improve NK cell therapy?
This method allows for efficient knockout of genes that regulate NK cell function, enhancing their therapeutic potential against tumors.
What is the significance of TGFBR2 in NK cells?
TGFBR2 is involved in immune regulation, and its deficiency can enhance NK cell activity against tumors.
What are the culture conditions for NK cells?
NK cells are cultured in RPMI medium supplemented with IL2, with specific conditions for primary and expanded cells.
Can this method be applied to other cell types?
While this protocol is designed for NK cells, similar techniques may be adapted for other immune cells.
Executive Industry Relevance
Efficient genome editing of primary human NK cells addresses a critical bottleneck in immunotherapy development, enabling mechanistic interrogation of immune evasion pathways such as TGF-beta signaling. This DNA-free Cas9/RNP approach improves target validation confidence by reducing procedure-associated apoptosis and increasing knockout efficiency, supporting de-risking of NK cell-based therapeutics. The method enhances translational continuity from discovery to preclinical evaluation by generating functionally modified NK cells that retain expansion capacity and cytotoxic potential.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of gene function in primary human NK cells to clarify roles of TGFBR2 and HPRT1 in effector cell regulation.
- Operational Value: Provides a high-success-rate alternative to viral transduction, minimizing apoptosis and improving yield of genetically modified NK cells.
- Predictive Value: Supports assessment of gene knockout impact on TGF-beta sensitivity, informing mechanistic de-risking of immunotherapy candidates.
Screening & Assay Development
- Scientific Value: Generates knockout NK cells suitable for functional assays, including cytotoxicity and gene expression analysis via RT-PCR and flow cytometry.
- Operational Value: Enables standardized preparation of edited NK cells using defined electroporation parameters (EN138 program) for reproducible transduction efficiency.
- Scalability: Supports post-electroporation expansion using irradiated mbIL21-expressing feeder cells, facilitating scale-up for downstream screening.
Translational & Preclinical Research
- Translational Relevance: Produces TGFBR2-deficient NK cells with reduced sensitivity to TGF-beta, modeling immune escape mechanisms in solid and brain tumors.
- Preclinical Continuity: Allows co-culture with tumor cell lines (e.g., medulloblastoma) to evaluate functional resistance to immunosuppressive cytokines.
- Risk-Adjusted Advancement: Enables evaluation of gene-edited NK cell persistence and function after modification, supporting go/no-go decisions in immunotherapy development.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, supporting target validation through gene knockout, enabling screening-ready cell products, and informing preclinical assessment of immunomodulatory resistance.
- Discovery Biology: Facilitates hypothesis testing of gene roles in NK cell effector function, particularly in TGF-beta-mediated immune suppression pathways.
- Screening: Generates assay-ready NK cells with quantifiable outputs (viability, transduction efficiency, gene expression) for compound or condition comparison.
- Analytics: Delivers measurable endpoints including mRNA reduction (60% for TGFBR2), viability rates, and cytotoxicity shifts for data-driven decision making.
- Translational Research: Connects genetic modification to functional outcomes in tumor co-culture models, supporting biomarker-aligned preclinical validation.
- Enterprise Reuse: Establishes a reusable workflow for NK cell editing that can be applied across multiple genetic targets and therapeutic programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by enabling efficient, DNA-free knockout in primary human NK cells.
- Operational Value: Improves reproducibility and standardization through defined electroporation conditions and feeder cell-based expansion.
- Strategic Value: Reduces biological risk in NK cell therapy development by clarifying gene function and immune escape mechanisms.
- Portfolio Impact: Supports risk-adjusted prioritization of immunotherapy targets through mechanistic de-risking of TGF-beta resistance pathways.
Implementation Considerations
- Requires expertise in primary NK cell isolation, culture, and electroporation techniques.
- Dependent on access to Nucleofector 4D system, Cas9 protein, and synthetic guide RNAs.
- Necessitates standardization of guide RNA design and validation across targets to ensure editing efficiency.
- Involves optimization of cell-to-complex ratios and incubation timing for RNP formation and delivery.
- Limited by primary NK cell donor variability and expansion potential post-electroporation.
Biopharma FAQs
Why is knockout efficiency critical for target validation in NK cells?
High knockout efficiency reduces false-negative results in gene function studies, increasing confidence in target role assignment. The Cas9/RNP method achieves efficient TGFBR2 and HPRT1 knockout in primary and expanded NK cells, overcoming limitations of viral transduction that induce apoptosis. This enables reliable interrogation of gene pathways regulating effector function and immune evasion.
How does isolation of the independent variable (gene knockout) support discovery pipeline objectives?
By generating isogenic NK cells with specific gene knockouts (e.g., TGFBR2), researchers can isolate the effect of single genetic modifications on cell function. This approach avoids confounding variables from polyclonal edits or viral integration, enabling clear attribution of phenotypic changes to the targeted gene. Such precision supports mechanistic de-risking in immunotherapy target selection.
What quantitative dependent variable measurements enable assessment of gene editing outcomes?
The method uses RT-PCR to quantify mRNA reduction (showing 60% decrease in TGFBR2 expression) and flow cytometry to assess viability and transduction efficiency. Cytotoxicity assays further evaluate functional impact, such as reduced sensitivity to TGF-beta in edited NK cells. These quantitative outputs allow objective comparison across conditions and guide optimization of editing parameters.
Why are replication requirements important for cross-functional collaboration in NK cell therapy development?
Reproducible editing efficiency across experiments and donors ensures that findings are transferable between discovery, preclinical, and clinical teams. The protocol specifies standardized conditions (e.g., EN138 program, feeder cell ratios) to enable consistent replication of knockout efficiency and functional outcomes. This supports aligned decision-making and reduces variability in multi-site or multi-stage immunotherapy programs.
What statistical analysis capabilities are required before implementing this method in a discovery workflow?
Implementation requires ability to quantify editing efficiency via T7E1 assay, RT-PCR, or sequencing, and to compare functional readouts (e.g., cytotoxicity, viability) between edited and control cells. Statistical comparison of gene expression levels and phenotypic changes enables objective assessment of knockout impact. These capabilities are essential for validating target engagement and supporting go/no-go decisions in immunotherapy programs.
